Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ubiquitin specific peptidase 2 | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific methyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ubiquitin specific protease, putative | ubiquitin specific peptidase 2 | 362 aa | 378 aa | 25.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0005 | 0.0127 | 0.0127 |
Leishmania major | ubiquitin hydrolase, putative,cysteine peptidase, Clan CA, family C19, putative | 0.0045 | 0.5839 | 0.5 |
Echinococcus granulosus | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0956 | 0.0587 |
Trichomonas vaginalis | Clan CA, family C19, ubiquitin hydrolase-like cysteine peptidase | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Trypanosoma cruzi | ubiquitin carboxyl-terminal hydrolase, putative | 0.0045 | 0.5839 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0045 | 0.5839 | 1 |
Brugia malayi | CXXC zinc finger family protein | 0.0035 | 0.4403 | 0.7071 |
Schistosoma mansoni | cpg binding protein | 0.0035 | 0.4403 | 0.4403 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Echinococcus granulosus | ubiquitin carboxyl terminal hydrolase 8 | 0.0045 | 0.5839 | 1 |
Echinococcus multilocularis | cpg binding protein | 0.0037 | 0.4688 | 0.7781 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Onchocerca volvulus | 0.0035 | 0.4403 | 0.5 | |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4688 | 0.4688 |
Plasmodium falciparum | zinc finger protein, putative | 0.0004 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Schistosoma mansoni | ubiquitin-specific peptidase 2 (C19 family) | 0.0045 | 0.5839 | 0.5839 |
Echinococcus granulosus | Peptidase C19 ubiquitin carboxyl terminal hydrolase 2 | 0.0045 | 0.5839 | 1 |
Giardia lamblia | Ubiquitin carboxyl-terminal hydrolase 4 | 0.0045 | 0.5839 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Brugia malayi | Ubiquitin carboxyl-terminal hydrolase family protein | 0.0045 | 0.5839 | 1 |
Trypanosoma brucei | ubiquitin carboxyl-terminal hydrolase, putative | 0.0045 | 0.5839 | 0.5 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Trypanosoma cruzi | ubiquitin carboxyl-terminal hydrolase, putative | 0.0045 | 0.5839 | 0.5 |
Echinococcus multilocularis | ubiquitin specific protease 41 | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Schistosoma mansoni | cpg binding protein | 0.0037 | 0.4688 | 0.4688 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Entamoeba histolytica | ubiquitin carboxyl-terminal hydrolase domain containing protein | 0.0045 | 0.5839 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | chromodomain-helicase-DNA-binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Echinococcus multilocularis | ubiquitin carboxyl terminal hydrolase 8 | 0.0045 | 0.5839 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET1 | 0.0066 | 0.8869 | 0.5 |
Trichomonas vaginalis | helicase, putative | 0.0008 | 0.0542 | 0.09 |
Schistosoma mansoni | ubiquitin-specific peptidase 8 (C19 family) | 0.0045 | 0.5839 | 0.5839 |
Echinococcus granulosus | cpg binding protein | 0.0037 | 0.4688 | 0.7781 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0035 | 0.4403 | 0.706 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Schistosoma mansoni | mixed-lineage leukemia protein mll | 0.0009 | 0.0651 | 0.0651 |
Echinococcus multilocularis | Peptidase C19, ubiquitin carboxyl terminal hydrolase 2 | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Echinococcus granulosus | ubiquitin specific protease 41 | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | Clan CA, family C19, ubiquitin hydrolase-like cysteine peptidase | 0.0045 | 0.5839 | 1 |
Trichomonas vaginalis | chromodomain helicase DNA binding protein, putative | 0.0008 | 0.0542 | 0.09 |
Echinococcus multilocularis | histone lysine N methyltransferase MLL3 | 0.0011 | 0.0956 | 0.0587 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0008 | 0.0542 | 0.09 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction. (Class of assay: confirmatory) [Related pubchem assays: 2698 (Summary assay.)] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.